Zhejiang Helixgen Pharmaceuticals

Helixgen Pharmaceuticals is a clinical-stage biopharmaceutical company headquartered in Shaoxing, China, specializing in the development of innovative small molecule drugs for oncology. The company's research focuses on precision medicine and targeted therapies designed to treat various forms of cancer with high unmet medical needs. Its lead program, HG030, is a second-generation TRK inhibitor developed to overcome resistance mutations in NTRK-fusion positive tumors and is currently in Phase 1/2 clinical development. Additionally, Helixgen is advancing HG3810, a dual FAK/FGFR inhibitor, through early-stage clinical trials for advanced solid tumors. The company is supported by a team of experienced scientists and backed by prominent Chinese venture capital firms.